Scott A Barros
Overview
Explore the profile of Scott A Barros including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
1059
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Janas M, Zlatev I, Liu J, Jiang Y, Barros S, Sutherland J, et al.
Nucleic Acids Res
. 2019 Mar;
47(7):3306-3320.
PMID: 30820542
For oligonucleotide therapeutics, chemical modifications of the sugar-phosphate backbone are frequently used to confer drug-like properties. Because 2'-deoxy-2'-fluoro (2'-F) nucleotides are not known to occur naturally, their safety profile was...
2.
Janas M, Jiang Y, Schlegel M, Waldron S, Kuchimanchi S, Barros S
Nucleic Acid Ther
. 2016 Dec;
27(1):11-22.
PMID: 27923110
Single-stranded (ss) 2'-fluoro (2'-F)-modified oligonucleotides (ONs) with a full phosphorothioate (PS) backbone have been reported to be cytotoxic and cause DNA double-strand breaks (DSBs) when transfected into HeLa cells. However,...
3.
Janas M, Jiang Y, Duncan R, Hayes A, Liu J, Kasperkovitz P, et al.
Nucleic Acid Ther
. 2016 Jul;
26(6):363-371.
PMID: 27387336
Registration of pharmaceuticals requires an assessment of their genotoxic potential using in vitro and in vivo tests outlined in the International Conference on Harmonisation (ICH) guidance S2(R1). We have evaluated...
4.
Berman C, Barros S, Galloway S, Kasper P, Oleson F, Priestley C, et al.
Nucleic Acid Ther
. 2016 Mar;
26(2):73-85.
PMID: 26978711
The Oligonucleotide Safety Working Group subcommittee on genotoxicity testing considers therapeutic oligonucleotides (ONs) unlikely to be genotoxic based on their properties and on the negative results for ONs tested to...
5.
Kumar V, Qin J, Jiang Y, Duncan R, Brigham B, Fishman S, et al.
Mol Ther Nucleic Acids
. 2014 Nov;
3:e210.
PMID: 25405467
Formulation of short interfering RNA (siRNA) into multicomponent lipid nanoparticles (LNP) is an effective strategy for hepatic delivery and therapeutic gene silencing. This study systematically evaluated the effect of polyethylene...
6.
Dong Y, Love K, Dorkin J, Sirirungruang S, Zhang Y, Chen D, et al.
Proc Natl Acad Sci U S A
. 2014 Feb;
111(11):3955-60.
PMID: 24516150
siRNA therapeutics have promise for the treatment of a wide range of genetic disorders. Motivated by lipoproteins, we report lipopeptide nanoparticles as potent and selective siRNA carriers with a wide...
7.
Barros S, Gollob J
Adv Drug Deliv Rev
. 2012 Jun;
64(15):1730-7.
PMID: 22732527
The emerging class of RNA interference (RNAi) therapeutics is a fundamentally novel approach to treating human disease by enabling the pursuit of molecular targets considered "undruggable" by small molecules and...
8.
Semple S, Akinc A, Chen J, Sandhu A, Mui B, Cho C, et al.
Nat Biotechnol
. 2010 Jan;
28(2):172-6.
PMID: 20081866
We adopted a rational approach to design cationic lipids for use in formulations to deliver small interfering RNA (siRNA). Starting with the ionizable cationic lipid 1,2-dilinoleyloxy-3-dimethylaminopropane (DLinDMA), a key lipid...
9.
Barros S, Srimaroeng C, Perry J, Walden R, Dembla-Rajpal N, Sweet D, et al.
J Biol Chem
. 2008 Nov;
284(5):2672-2679.
PMID: 19028678
Organic anion transporters (OATs) play a pivotal role in the clearance of small organic anions by the kidney, yet little is known about how their activity is regulated. A yeast...
10.
Barros S, Martin R
Methods Mol Biol
. 2008 May;
460:89-112.
PMID: 18449484
The failure of drug candidates during clinical trials due to toxicity, especially hepatotoxicity, is an important and continuing problem in the pharmaceutical industry. This chapter explores new predictive toxicogenomics approaches...